M&A Healthcare Advisors (“MAHA”) is pleased to present an ACHC accredited hospice provider with two locations in Southern California. The business was established in 2012 and has over 60 employees. The current patient census is approximately 130 patients. From 2023 through March of 2024, approximately 80% of the revenue can be attributed to Medicare. Financial Overview: 2021 2022 2023 TTM-Mar 24 Net Revenue 9.5M 12.9M 11.2M 10.7M Gross Profit 6.0M 7.8M 7.4M 7.3M Adj. EBITDA 3.4M 1.7M 2.2M 2.5M Ownership consists of two (2) owners who each hold 50% of the agency. One owner functions as the Administrator while the other has a reduced role in day-to-day operations. Ownership is collectively looking for a full exit to explore other opportunities. Both owners are available to assist in a transitionary period and all employees, including additional management, are expected to remain.

M&A Healthcare Advisors is pleased to present Project Synergy, a non-surgical & integrative medicine clinic focused on serving patients with chronic pain and illness. The company has been in business for over 30 years and serves patients in Virginia, Maryland, Washington DC and other states throughout the country (telehealth services). The clinic is based in Virgina (near Washington DC) and offers a multitude of services including Long-COVID recovery services, Physical Therapy, Nutrition, Telehealth, Psychotherapy, Acupuncture, Supplements, Herbal Remedies, & more. There are currently 3 active physicians and a provider staff including Registered Nurses, Physical Therapists, a Nutritionist, Acupuncturist, Therapist, & Medical Assistants. Nearly all revenue is generated through private pay, and they offer a unique membership model on an annual basis to willing patients (currently 139 members). They have an active census of over 1,200 and are expected to generate over $4 million of revenue in 2024 with an EBITDA margin of approximately 20%. Current opportunities exist to grow the business which are detailed in the CIM. The company is led by a physician pioneer and thought leader for integrative medicine who intends to remain with the practice post-acquisition. For more information, please complete our Non-Disclosure Agreement

M&A Healthcare Advisors is pleased to present Project Apollo, a specialty pharmacy focused on treating a single, rare genetic disorder. This single-location pharmacy, founded over 10 years ago, is licensed in 30 states and serves patients in 6 states. Patient reimbursements primarily flow through the pharmacy Medicaid program ($47.71M), with most of the dispensing occurring in the state where the headquarters are located. $15.59M is from contracts with third party pharmacies in multiple states who dispense on behalf of Apollo and $8.71M is billed through a university health system contract with a portion of 340B patients. In 2023, sales representatives accounted for 30% of patient revenues with the balance earned under house accounts. Historically, patient retention has remained at 85%. The pharmacy has a record of consistent revenue and profitability. 2022 Adj. Revenue: $76.5M, 2022 Adj. EBITDA: $900,000. 2023 Adj. Revenue: $70.5M, 2023 Adj. EBITDA: $2.35M. The company is led by a strong management team and 20-25 employees. Certain owners are looking to fully exit, while others are willing to remain involved. All owners are available to assist through the necessary transition period, post-close.

M&A Healthcare Advisors is pleased to present an aesthetics practice providing Plastic Surgery and Med Spa services to patients in the Upper Midwest. The business was established over 20 years ago and offers a wide range of cosmetic surgeries and non-invasive cosmetic procedures. It operates out of 3 locations with 11 treatment rooms and 15 employees. Their main location is a stand-alone cosmetic clinic and Quad A certified surgery center. The practice has served over 21,800 patients in its lifetime. While most services are private pay, approximately 15% of the services are covered by insurance. Non-surgical procedures include injectables, Cool Tone, Coolsculpting, Miradry, laser treatments and more. Surgical procedures include breast augmentation, liposuction, abdominoplasty, and more. The company also has a thriving testosterone practice and recently introduced Semaglutide therapies this year. In 2022, revenues and adjusted EBITDA were approximately $2.8 million and $456K (16%) respectively. TTM revenue ending September 2023 is $2.5 million with an adjusted EBITDA of $406K (16%). For YTD (Jan-Sept.) 2023, approximately $822K (53%) of revenue was generated from surgery services and $740K (47%) from non-surgical procedures.   Our client is the company’s CEO and plastic surgeon who would like to retire near term but is open to remaining with the business long enough to ensure a successful transition. For more information and next steps, please sign our Non-Disclosure Agreement.

M&A Healthcare Advisors is pleased to present a Primary Care Practice with multiple offices located in Central Coast California. The business was established over 40 years ago and offers a wide range of services including Comprehensive Primary Care, Dermatology Evaluations, Women’s Health, Primary Mental Health Care, Minor Surgical procedures, and more. There are currently 5 Physicians and 5 Physician Assistants within the practice. For 2023, the payor breakdown is approximately Medi-Cal (39%), HMO (25%), PPO (18%), Medicare (17%), and Private Pay (1%). As of August 2023, the company’s patient census is over 15,000 and on average, providers perform approximately 1,900 patient visits per month. 2023 is also experiencing increased numbers in terms of patient growth whereas June through August saw an average of 195 new patients each month. In 2020 and 2021, the company generated revenue of approximately $5.3 million ($1.530 million Adj. EBITDA) and $5.8 million ($1.537 million Adj. EBITDA), respectively. In 2022, the company generated nearly $6.5 million of revenue with an adjusted EBITDA of approximately $1.475 million (23%). Due to several external factors, including less favorable PPO rates, the company’s Trailing Twelve Months (TTM) revenue ending August 2023 is approximately $6 million with an adjusted EBITDA of $530,000 (9%). Q4 of 2023 is expected to outperform the prior months while 2024 is projected to yield comparable financial results to 2022. Our client is the company’s CEO & Medical Director. He would like to retire near term but is open to remaining with the business long enough to ensure a successful transition. For more information and next steps, please sign our Non-Disclosure Agreement.